GO
Loading...

Amgen Inc

More

  • Midday Glance: Biotechnology companies Thursday, 13 Nov 2014 | 1:27 PM ET

    Amgen Inc. fell $1.09 or. 7 percent, to $160.84. Biogen Idec fell $3.04 or. 9 percent, to $317.98. Celgene Corp. fell$. 65 or. 6 percent, to $107.60.

  • Early Glance: Biotechnology companies Thursday, 13 Nov 2014 | 12:16 PM ET

    Amgen Inc. fell$. 55 or. 3 percent, to $161.38. Biogen Idec rose$. 33 or. 1 percent, to $321.35. Celgene Corp. rose$. 11 or. 1 percent, to $108.36.

  • Final Glance: Biotechnology companies Wednesday, 12 Nov 2014 | 6:02 PM ET

    Amgen Inc. fell$. 49 or. 3 percent, to $161.93. Biogen Idec fell $3.57 or 1.1 percent, to $321.02. Celgene Corp. rose$. 40 or. 4 percent, to $108.25.

  • Midday Glance: Biotechnology companies Wednesday, 12 Nov 2014 | 1:23 PM ET

    Amgen Inc. fell$. 19 or. 1 percent, to $162.23. Biogen Idec fell $2.98 or. 9 percent, to $321.61. Celgene Corp. fell$. 04 or percent, to $107.81.

  • Early Glance: Biotechnology companies Wednesday, 12 Nov 2014 | 11:05 AM ET

    Amgen Inc. rose$. 08 or percent, to $162.50. Biogen Idec fell $2.03 or. 6 percent, to $322.56. Celgene Corp. fell$. 55 or. 5 percent, to $107.30.

  • Final Glance: Biotechnology companies Tuesday, 11 Nov 2014 | 6:01 PM ET

    Amgen Inc. fell$. 67 or. 4 percent, to $162.42. Biogen Idec fell $3.28 or 1.0 percent, to $324.59. Celgene Corp. fell$. 16 or. 1 percent, to $107.85.

  • Midday Glance: Biotechnology companies Tuesday, 11 Nov 2014 | 1:52 PM ET

    Amgen Inc. fell$. 14 or. 1 percent, to $162.95. Biogen Idec fell $3.20 or 1.0 percent, to $324.67. Celgene Corp. rose$. 04 or percent, to $108.05.

  • Early Glance: Biotechnology companies Tuesday, 11 Nov 2014 | 10:32 AM ET

    Amgen Inc. fell$. 05 or percent, to $163.04. Biogen Idec rose $1.53 or. 5 percent, to $329.40. Celgene Corp. fell$. 01 or percent, to $108.00.

  • Final Glance: Biotechnology companies Monday, 10 Nov 2014 | 6:07 PM ET

    Amgen Inc. rose $3.45 or 2.2 percent, to $163.09. Biogen Idec rose $7.12 or 2.2 percent, to $327.87. Celgene Corp. rose $1.56 or 1.5 percent, to $108.01.

  • Midday Glance: Biotechnology companies Monday, 10 Nov 2014 | 1:28 PM ET

    Amgen Inc. rose $2.39 or 1.5 percent, to $162.03. Biogen Idec rose $4.15 or 1.3 percent, to $324.90. Celgene Corp. rose $1.12 or 1.1 percent, to $107.57.

  • Early Glance: Biotechnology companies Monday, 10 Nov 2014 | 10:28 AM ET

    Amgen Inc. rose $1.51 or. 9 percent, to $161.15. Biogen Idec rose$. 81 or. 3 percent, to $321.56. Celgene Corp. rose$. 01 or percent, to $106.46.

  • Nov 4- Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Jefferies analysts in a note published on Oct. 20 said oncologists expect the drug to have little or no benefits in terms of overall survival. "Thus, FDA approval is unlikely in our view," they wrote.

  • *U.S. dollar softens as market braces for dovish message from Fed. SYDNEY, Oct 29- The U.S. dollar was subdued early on Wednesday as investors waited for the latest guidance from the Federal Reserve, while a surprisingly dovish message from Sweden's central bank saw the crown slump to four-year lows. "In our view, the Riksbank's dovish forward guidance has pushed the...

  • *Amgen gains, Twitter falls following results. Amgen's stock was up 5.1 percent, among the top boosts for the S&P 500 and Nasdaq, following its results and forecast, while energy shares bounced back sharply from big declines Monday. "Companies are managing to outperform in a period when the global economy is slowing," said Peter Cardillo, chief market economist at...

  • NEW YORK, Oct 28- Amgen Inc, which has come under investor pressure to split the company, said Tuesday it has no plans to do so and forecast 2015 earnings and revenue well ahead of analysts' projections, sending shares up 5 percent. Chief Executive Robert Bradway said the company had considered the option of splitting into mature and growth product businesses- as...

  • US STOCKS-Wall St climbs on earnings, confidence data Tuesday, 28 Oct 2014 | 1:32 PM ET

    *Amgen gains, Twitter falls following results. NEW YORK, Oct 28- U.S. stocks climbed in afternoon trading on Tuesday, following stronger-than-expected earnings and an upbeat consumer confidence reading. Amgen's stock was up 5 percent, among the top boosts for the S&P 500 and Nasdaq, following its results and guidance, while energy shares reboundedbounced back...

  • US STOCKS-Earnings lift Wall St despite mixed data Tuesday, 28 Oct 2014 | 12:00 PM ET

    *Twitter falls; Madison Square Garden up on possible split. *Capital goods orders post largest fall in eight months. Ranking among the largest percentage gainers on the S&P 500 were Amgen, AutoNation and Cummins, which reported earnings between late Monday and Tuesday morning.

  • Amgen CEO: We're not splitting up Tuesday, 28 Oct 2014 | 11:31 AM ET
    An Amgen sign is seen at the company's office in South San Francisco, California.

    Amgen's CEO provided an answer to Dan Loeb's recent suggestion that the biotechnology company be split up. In short, he said, it doesn't make sense.

  • US STOCKS-Wall St up on earnings, data mixed Tuesday, 28 Oct 2014 | 10:52 AM ET

    *Capital goods orders post largest fall in eight months. NEW YORK, Oct 28- U.S. stocks rose on Tuesday as strong earnings and an upbeat consumer confidence reading more than offset weaker-than-expected housing and industrial data. Ranking among the largest percentage gainers on the S&P 500 were Amgen, AutoNation and Cummins, which reported earnings between...

  • Amgen CEO: Not planning on split     Tuesday, 28 Oct 2014 | 9:13 AM ET

    At Amgen's investor meeting, CNBC's Meg Tirrell reports CEO Bob Bradway said the company considered splitting up but does not see it adding value right now.